KAF156
Total Payments
$846,077
Transactions
1
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2018 | $846,077 | 1 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $846,077 | 1 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED SINGLE CENTER 5 WEEK STUDY TO EVALUATE THE SAFETY AND CAUSAL PROPHYLACTIC EFFICACY OF KAF156 IN A CONTROLLED HUMAN MALARIA CHALLENGE CHMI | Novartis Pharmaceuticals Corporation | $846,077 | 0 |
Top Doctors Receiving Payments for KAF156
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Seattle, WA | $846,077 | 1 |
Ad
Manufacturing Companies
- Novartis Pharmaceuticals Corporation $846,077
Product Information
- Type Drug
- Total Payments $846,077
- Total Doctors 0
- Transactions 1
About KAF156
KAF156 is a drug associated with $846,077 in payments to 0 healthcare providers, recorded across 1 transactions in the CMS Open Payments database. The primary manufacturer is Novartis Pharmaceuticals Corporation.
Payment data is available from 2018 to 2018. In 2018, $846,077 was paid across 1 transactions to 0 doctors.
The most common payment nature for KAF156 is "Unspecified" ($846,077, 100.0% of total).
KAF156 is associated with 1 research study, including "A RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED SINGLE CENTER 5 WEEK STUDY TO EVALUATE THE SAFETY AND CAUSAL PROPHYLACTIC EFFICACY OF KAF156 IN A CONTROLLED HUMAN MALARIA CHALLENGE CHMI" ($846,077).